UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA

5/27/25 4:00:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $URGN alert in real time by email

UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a fireside chat at the TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA to take place on May 27-28, 2025.

TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Date / Time:		May 28, 2025, at 9:00 AM ET
Format:		Fireside Chat
Location:		Virtual
Webcast Link:		here

Webcasts from the conferences will also be available on UroGen's Investor Relations website. A replay will be available on the site for approximately 90 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel^® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with recurrent low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X (Twitter), @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250527694477/en/

INVESTORS:

Vincent Perrone

Senior Director, Investor Relations

[email protected]

609-460-3588 ext. 1093

MEDIA:

Cindy Romano

Director, Corporate Communications

[email protected]

609-460-3583 ext. 1083

Get the next $URGN alert in real time by email

Recent Analyst Ratings for

$URGN

Date	Price Target	Rating	Analyst
6/16/2025	$50.00	Neutral → Buy	H.C. Wainwright
5/22/2025		Buy → Neutral	H.C. Wainwright
4/16/2025	$23.00	Sector Outperform	Scotiabank
2/19/2025	$31.00	Buy	Ladenburg Thalmann
8/22/2024	$40.00	Buy	Guggenheim
2/8/2023	$35.00 → $10.00	Buy → Hold	Jefferies
4/27/2022	$20.00	Buy	Berenberg
1/18/2022	$50.00 → $34.00	Buy	HC Wainwright & Co.

More analyst ratings

UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Chat with this insight

Recent Analyst Ratings for
$URGN

$URGN
SEC Filings

SEC Form 8-K filed by UroGen Pharma Ltd.

Amendment: SEC Form SCHEDULE 13D/A filed by UroGen Pharma Ltd.

Amendment: SEC Form SCHEDULE 13G/A filed by UroGen Pharma Ltd.

$URGN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Schoenberg Mark converted options into 10,000 units of Ordinary Shares and sold $38,044 worth of Ordinary Shares (5,162 units at $7.37), increasing direct ownership by 3% to 153,378 units (SEC Form 4)

Chief Medical Officer Schoenberg Mark converted options into 8,000 units of Ordinary Shares and sold $50,698 worth of Ordinary Shares (4,551 units at $11.14), increasing direct ownership by 2% to 148,540 units (SEC Form 4)

General Counsel Smith Jason Drew converted options into 14,667 units of Ordinary Shares and sold $82,202 worth of Ordinary Shares (7,379 units at $11.14), increasing direct ownership by 29% to 32,514 units (SEC Form 4)

UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Chat with this insight

Recent Analyst Ratings for $URGN

$URGN SEC Filings

SEC Form 8-K filed by UroGen Pharma Ltd.

Amendment: SEC Form SCHEDULE 13D/A filed by UroGen Pharma Ltd.

Amendment: SEC Form SCHEDULE 13G/A filed by UroGen Pharma Ltd.

$URGN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Schoenberg Mark converted options into 10,000 units of Ordinary Shares and sold $38,044 worth of Ordinary Shares (5,162 units at $7.37), increasing direct ownership by 3% to 153,378 units (SEC Form 4)

Chief Medical Officer Schoenberg Mark converted options into 8,000 units of Ordinary Shares and sold $50,698 worth of Ordinary Shares (4,551 units at $11.14), increasing direct ownership by 2% to 148,540 units (SEC Form 4)

General Counsel Smith Jason Drew converted options into 14,667 units of Ordinary Shares and sold $82,202 worth of Ordinary Shares (7,379 units at $11.14), increasing direct ownership by 29% to 32,514 units (SEC Form 4)

Recent Analyst Ratings for
$URGN

$URGN
SEC Filings

$URGN
Insider Trading